World Vaccine Congress Europe 2026 has ended. This guide stays up as the record of who was there. Next: WVC Europe 2027, Oct 25–27, 2027 in Lyon
Biotech companies at World Vaccine Congress Europe 2026
Oct 19–21, 2026 Amsterdam, Netherlands ~2k attendees Website
49 biotech companies are at World Vaccine Congress Europe 2026 — 56 presentations on the program and 33 with a booth in the exhibit hall. Most represented: Tonix Pharmaceuticals (3 on the program), DIOSynVax (2 on the program), Abera Bioscience (2 on the program). 39 of them have their own page in this guide. As of Oct 12, 2026.
All 268 organizations at World Vaccine Congress Europe 2026 →
| Organization | World Vaccine Congress Europe 2026 Attendance |
|---|---|
Tonix Pharmaceuticals Chatham, NJ | |
Biopharmaceutical company whose vaccine work includes TNX-801, a horsepox-based vaccine platform. | Booth Exhibiting (no floor booth listed) Talk Tue Oct 20 11:30 Working Group: Vectored Vaccine Platforms: from design to improving efficacy Platforms & delivery Talk Wed Oct 21 13:15 |
DIOSynVax Cambridge, United Kingdom | |
Uses computational antigen design to develop broadly protective vaccines against influenza, coronaviruses and other viral threats. | Talk Mon Oct 19 11:15 Session Tue Oct 20 14:00 Session Tue Oct 20 16:00 Talk Wed Oct 21 13:45 |
Develops mucosal vaccines against serious infectious diseases on a proprietary platform of outer membrane vesicles (OMVs). | Booth Exhibiting (no floor booth listed) Talk Mon Oct 19 10:30 Talk Wed Oct 21 10:30 From Innovation to Impact: Translating OMV Vaccine Technology into Clinical Reality How a developer and a contract manufacturer take vaccines made from outer membrane vesicles, tiny bacterial bubbles, from research toward clinical trials. |
Uses its AI-Immunology platform to discover and design vaccines against bacterial and viral infections and cancer. | Booth Exhibiting at Booth 216 Talk Wed Oct 21 11:00 Talk Wed Oct 21 11:30 |
Session Wed Oct 21 10:30 Session Wed Oct 21 12:15 | |
Inimmune Missoula, MT | |
Biotech designing and developing TLR agonist adjuvants and immunotherapeutics. | Talk Mon Oct 19 14:00 Talk Wed Oct 21 10:45 |
Develops vaccines against zoonotic and animal diseases using herpesvirus vectors. | Session Wed Oct 21 10:30 Session Wed Oct 21 13:15 |
Develops bacteriophage treatments, viruses that kill bacteria, as an answer to antibiotic resistance, starting with cholera. | Booth Exhibiting at Booth SU4 Talk Tue Oct 20 12:50 Start-up Pitch 3: PhagePro Infectious disease & AMR |
Vaxxirna Houston, TX | |
Develops circular RNA vaccines for infectious diseases, with heat-stable lipid nanoparticle formulations and microneedle patch delivery. | Booth Exhibiting (no floor booth listed) Talk Tue Oct 20 16:00 Safe and Efficacious Circular RNA Vaccines to Treat Yellow Fever and Dengue Infectious disease & AMRPlatforms & delivery |
SB Sagitta Biotech | |
Develops targeted viral vectors that deliver toxic payloads to solid tumors, with efficacy data in glioblastoma. | Talk Wed Oct 21 10:40 |
HL Hilleman Laboratories Singapore, Singapore | |
Vaccine research and development organization, founded by MSD and Wellcome, developing affordable vaccines for low- and middle-income countries. | Booth Exhibiting (no floor booth listed) Talk Tue Oct 20 11:30 Working Group: Partnerships for Prevention: Accelerating Vaccines to Curb Antimicrobial Resistance How partnerships across sectors could speed up and widen access to vaccines against drug-resistant bacteria, such as a maternal Klebsiella vaccine for newborns. Infectious disease & AMRSupply, safety & access Talk Wed Oct 21 09:00 The New Geopolitics of Vaccines: Global Vaccine Manufacturing in a Fractured World How governments and industry can keep vaccines flowing fairly across borders in an emergency as countries push to make vaccines at home. Supply, safety & accessBioprocess & manufacturing Talk Wed Oct 21 12:15 Panel: The New Geography of Vaccine Innovation: Why the Next Decade of Vaccine Development Will Be Driven by LMICs Why low- and middle-income countries are becoming vaccine innovators, not just trial sites, and what funding and regional regulatory cooperation they need. |
Session Wed Oct 21 10:30 Talk Wed Oct 21 10:30 Session Wed Oct 21 13:45 | |
Spanish vaccine company in the Zendal group developing and manufacturing the MTBVAC tuberculosis vaccine. | Talk Wed Oct 21 12:45 Panel Wed Oct 21 14:30 Panel: Can TB vaccines deliver on the promise? What tuberculosis vaccine trials can learn from COVID-19, flu and respiratory syncytial virus, and how to make tuberculosis a funding priority. |
Find buyers from biotech companies
Tell us what you sell and we’ll find the people at these biotech companies most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Browse World Vaccine Congress Europe 2026 by
Not affiliated with or endorsed by the World Vaccine Congress or its organizers. Submit a correction